Fevertree Drinks PLC Total Voting Rights

RNS Number : 4117C

Fevertree Drinks PLC

02 September 2024

 

2 September 2024

 

Fevertree Drinks plc

 ("Fever-Tree" or the "Company")

 

Total Voting Rights

 

The Company's total issued share capital consists of 116,736,657 ordinary shares of 0.25p each ("Ordinary Shares") with one voting right per Ordinary Share. The Company does not hold any Ordinary Shares in Treasury.

Therefore, the total number of voting rights in the Company is 116,736,657. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

Ends

 

For further information:

 

Investor queries

Ann Hyams, Director of Investor Relations I [e-mail] I [phone]

 

Media queries

Oliver Winters, Director of Communications I [e-mail] I [phone]

 

Nominated Advisor and Broker - Investec Bank plc

David Flin I [phone]

 

Corporate Broker - Morgan Stanley & Co. International plc

Andrew Foster I Jessica Pauley I [phone]

 

Financial PR advisers - FGS Global

Faeth Birch [phone] I Anjali Unnikrishnan [phone]

Notes to Editors:

Fever-Tree is the world's leading supplier of premium carbonated mixers for alcoholic spirits by retail sales value, with distribution to over 85 countries worldwide. Based in the UK, the brand was launched in 2005 to provide high quality mixers which could cater to the growing demand for premium spirits, in particular gin, but also increasingly for vodka, rum and whisky. The Company now sells a range of carbonated mixers to hotels, restaurants, bars and cafes ("On Trade") as well as selected retail outlets ("Off Trade").

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

TVREAEPFDFPLEEA